cell stress Archives - Sanford Burnham Prebys
Institute News

Cell stress response bears good news and bad news for liver cancer

AuthorGreg Calhoun
Date

February 12, 2026

Cell stress response protein implicated in cancer progression, yet it also weakens resistance to immunotherapies

Metabolic disorders such as obesity and type 2 diabetes place extra stress on the liver. Liver cells try to protect themselves from the accompanying surge in dysfunctional proteins by activating factors that help restore an appropriate protein balance.

One of these factors is a protein called activating transcription factor 6 alpha (ATF6α) that was recently shown to drive the onset of liver cancer if left permanently active. In a Nature study published February 4, 2026, an international team of scientists demonstrated that activating ATF6α in mice caused liver disease that progressed to liver cancer.

In data from human liver cancer patients, ATF6α activation was linked with more aggressive tumors, a suppressed immune system surrounding tumors and reduced patient survival.

The researchers also uncovered ways that ATF6α might be used to advance the treatment of liver cancer. Liver cells with ATF6α switched off developed fewer tumors. While high ATF6α activity levels were associated with cancer progression, they also were found to make tumors more susceptible to certain immunotherapies.

These findings suggest the need for future clinical trials to test drugs that directly target ATF6α to treat the disease. Additionally, it might prove advantageous to screen liver cancer patients for ATF6α activity to find those most likely to benefit from existing immunotherapies.

Portrait of Randal J. Kaufman, PhD

Randal Kaufman, PhD, is a professor in the Center for Metabolic and Liver Diseases at Sanford Burnham Prebys and a co-corresponding author of the study. Image credit: Sanford Burnham Prebys.

To learn more, read the German Cancer Research Center press release.


Xin Li, PhD, a postdoctoral fellow at the German Cancer Research Center (DKFZ), shares first authorship of the study with co-corresponding author Cynthia Lebeaupin, PhD, principal scientist at Pfizer and former postdoctoral researcher at Sanford Burnham Prebys Medical Discovery Institute.

The other co-corresponding authors are Dirk Haller, PhD, Technische Universität München; Randal Kaufman, PhD, Sanford Burnham Prebys; and Mathias Heikenwälder, PhD, University of Tübingen and DKFZ.

Institute News

High levels of protein p62 predict liver cancer recurrence

AuthorJessica Moore
Date

May 19, 2016

CANCER METABOLISM AND SIGNALING NETWORKS PROGRAM

New research from SBP and UC San Diego shows that high levels of the protein p62 in human liver samples are strongly associated with cancer recurrence and reduced patient survival. p62 was also found to be required for liver cancer to form in mice. Continue reading “High levels of protein p62 predict liver cancer recurrence”

Institute News

Antioxidant-rich diet could help stave off type 2 diabetes

AuthorGuest Blogger
Date

November 12, 2015

Type 2 diabetes affects about 8% of all adults and is a leading cause of death worldwide. Despite its prevalence, relatively little is known about underlying molecular causes of the disease. SBP researchers now show that defects in a major cell stress pathway play a key role in the failure of pancreatic beta cells, leading to signs of diabetes in mice. The findings, published recently in PLOS Biology, also suggest that a diet rich in antioxidants could help to prevent or treat type 2 diabetes.

“The findings open new therapeutic options to preserve beta cell function and treat diabetes,” said senior study author Randal Kaufman, PhD, director of the Degenerative Diseases Program at SBP. “Because the same cell stress response is implicated in a broad range of diseases, our findings suggest that antioxidant treatment may be a promising therapeutic approach not only for metabolic disease, but also neurodegenerative diseases, inflammatory diseases, and cancer.”

Excess cell stress

Type 2 diabetes is caused by the failure of pancreatic beta cells to produce enough insulin—a hormone that helps to move a blood sugar called glucose into cells to be stored for energy. A major cause of type 2 diabetes is obesity, which can lead to abnormalities in insulin signaling and high blood glucose levels. Beta cells try to compensate by producing up to 10 times the usual amount of insulin, but this puts extra stress on a cell structure called the endoplasmic reticulum to properly fold, process, and secrete the hormone.

An increase in protein synthesis in beta cells also causes oxidative stress—a process that can lead to cell damage and death through the build-up of toxic molecules called reactive oxygen species. If the stress is too great, the beta cells will eventually fail. Approximately one-third of individuals with abnormal insulin signaling eventually develop beta cell failure and diabetes.

In the new study, Kaufman and his collaborators discovered that beta cell failure is caused by deficiency in a protein called IRE1α, which would otherwise help to protect cells against the stress of increased insulin production. Mice that lacked IRE1α in pancreatic beta cells did not produce enough insulin and developed high blood glucose levels, similar to patients with type 2 diabetes. IRE1α deficiency also caused inflammation and oxidative stress, which was the primary cause of beta cell failure. But treatment with antioxidants, which prevented the production of reactive oxygen species, significantly reduced metabolic abnormalities, inflammation and oxidative stress in these mice.

Taken together, the findings suggest that IRE1α evolved to expand the capacity of beta cells to produce insulin in response to increases in blood glucose levels. The study also implicates this major cell stress pathway in the development of type 2 diabetes and suggests that a diet rich in antioxidants could help to prevent or reduce the severity of the disease.

“Currently, we are testing the effects of antioxidants on glucose levels and beta cell function in mice,” Kaufman said. “If these studies prove successful, they could pave the way for clinical trials in humans and eventually lead to a new therapeutic approach for dealing with a major pandemic of the 21st century.”

This post was written by guest blogger Janelle Weaver, PhD